AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
HYANNIS, MASS. -- Antiretroviral therapy can markedly reduce vertical HIV transmission in pregnant women, but drug choices and dosages need to be carefully tailored to optimize efficacy and minimize potential toxicities, according to Dr. Deborah Money.
A cohort study of HIV-infected pregnant women and infants treated between 1990 and 2002 at a Canadian tertiary referral center showed that women who took prenatal antiretroviral therapy (ART) had a 0% vertical transmission rate. In addition, women on nonnucleoside regimens had higher rates of significant toxicity than women taking protease inhibitors, Dr. Money reported at the annual meeting of the Infectious Diseases Society for Obstetrics and Gynecology
Of 218 HIV-infected pregnant women (247 live births) seen during the study period at the Children's and Women's Health Centre of British Columbia, 152 of the mothers received some form of ART: 123 received more than 2 weeks of prenatal therapy, and 29 received intrapartum treatment alone.
The prenatal ART group included 24 women on AZT, 12 on dual nucleosides, and 87 on highly active antiretroviral therapy (HAART). The various HAART regimens included 1 triple nucleoside regimen, 42 protease inhibitor (PI) regimens, 42 nonnucleoside reverse transcriptase inhibitor (NNRTI) regimens, and 2 multidrug salvage regimens. Four of the patients taking NNRTI regimens switched to PI therapy later in pregnancy, said Dr. Money, head of the maternal ...